“We really try to be careful about testing, especially when it's a potential burden of costs on the patient. What we really look at is where it's going to have an impact,” says Stephen J. Savage, MD.
In this interview, Stephen J. Savage, MD, discusses current research he’s working on, the role of molecular testing in prostate cancer as well as unmet needs in treating the disease. Savage is director of minimally invasive urology at the Medical University of South Carolina, Charleston.